Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06397131 · ClinicalTrials.gov registry record · Phase 3
A Study to Determine the Safety and Efficacy of NT-501 With MHFM
A Phase 3 study of Macular Telangiectasia Type 2, sponsored by Neurotech Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT06397131: Active Phase 3 study of Macular Telangiectasia Type 2, sponsored by Neurotech Pharmaceuticals.
NCT06397131 is a Phase 3 study of Macular Telangiectasia Type 2 that is active but no longer recruiting, run by Neurotech Pharmaceuticals. The registered enrollment target is 12 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06397131, a Phase 3 study of Macular Telangiectasia Type 2, is active but no longer recruiting, sponsored by Neurotech Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is to determine the long-term levels of CNTF, and the clinical safety and efficacy of the NT-501 implants with the Medica Hollow Fiber Membrane (MHFM) in participants with macular telangiectasia type 2.
Primary Outcome
Rate of change in EZ area loss as measured by en face imaging by Spectral-Domain Optical Coherence Tomography (SD-OCT) in the study eye.
Conditions Studied
Interventions
- COMBINATION_PRODUCT NT-501 CNTF Implant
Study Locations (3)
California
- Bay Area Retina Associates, A Medical Group - Walnut Creek
Michigan
- Foundation for Vision Research - Grand Rapids
Texas
- Retina Consultants of Texas - Bellaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-03-06 |
| Est. Completion | 2026-07-24 |
| Phase | Phase 3 |
What the registry record for NCT06397131 still lists
NCT06397131 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Macular Telangiectasia Type 2 appearing as the primary indexed condition, and to 1 intervention - of which NT-501 CNTF Implant is the first listed.
NCT06397131 reports a single indexed study location in California, Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT06397131 about?
NCT06397131 is a clinical study titled "A Study to Determine the Safety and Efficacy of NT-501 With MHFM". This study is to determine the long-term levels of CNTF, and the clinical safety and efficacy of the NT-501 implants with the Medica Hollow Fiber Membrane (MHFM) in participants with macular telangiectasia type 2.
What is the current status of trial NCT06397131?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2025-03-06. Estimated completion is 2026-07-24.
What conditions does trial NCT06397131 study?
This clinical trial studies the following conditions: Macular Telangiectasia Type 2.
What interventions are being tested in trial NCT06397131?
The interventions under investigation include: NT-501 CNTF Implant (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06397131?
This trial is sponsored by Neurotech Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06397131 being conducted?
This trial has 3 study locations across California, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Telangiectasia Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06397131's enrollment target sits among peer trials
12 1984th of 2000 higher than 12 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI